top of page
Antibody System Anti-Vosoritide ELISA Kit

Antibody System Anti-Vosoritide ELISA Kit

Overview
This enzyme-linked immunosorbent assay (ELISA) kit is engineered for the precise quantitative determination of Anti-Vosoritide antibody concentrations in serum and plasma samples. Vosoritide is a modified recombinant human C-type natriuretic peptide (CNP) analog composed of 39 amino acids, featuring an extended N-terminus that prolongs its half-life by resisting neutral endopeptidase degradation. Administered primarily to treat achondroplasia—the most common form of human dwarfism—Vosoritide acts as a targeted therapeutic agent by binding specifically to Natriuretic Peptide Receptor B (NPR-B) to promote endochondral bone growth and chondrocyte proliferation. However, chronic administration can prompt an immune response leading to the generation of anti-drug antibodies (ADAs). This specialized ELISA platform is optimized for detecting and quantifying total anti-drug antibodies generated against Vosoritide, acting as a critical analytical instrument for clinical investigators, geneticists, and pharmacologists tracking long-term therapeutic immunogenicity, analyzing secondary drug resistance, and evaluating pharmacokinetic clearance variations.
 
DATASHEET

  • PRODUCT INFO

    Principle of the Assay

    This assay utilizes a high-performance, solid-phase quantitative sandwich enzyme immunoassay technique (bridging format) to measure specific anti-drug antibody levels:

    • Target Capture: Recombinant Vosoritide is uniformly pre-coated onto the solid-phase surface of a 96-well microplate.

    • Specific Binding: Calibrated standards or unknown biological samples are pipetted directly into the microwells. Endogenous Anti-Vosoritide antibodies present in the sample are bound and captured by the immobilized Vosoritide proteins.

    • Bridging Conjugation: Unbound matrix elements are removed via a rigorous wash cycle. A biotin-labeled Vosoritide tracer solution is introduced into the wells, binding to the open antigen-binding sites of the captured Anti-Vosoritide target, effectively forming an immune bridging complex.

    • Enzyme Complexing: Following another wash step to clear unbound tracer, Streptavidin conjugated to Horseradish Peroxidase (Streptavidin-HRP) is added to bind specifically to the biotinylated domains.

    • Signal Amplification and Readout: After a final wash to remove excess enzyme reagent, a colorimetric substrate solution is added to initiate enzymatic signal development. Because this is a bridging sandwich assembly, the resulting color intensity develops in direct proportion to the concentration of Anti-Vosoritide bound in the initial step. The reaction is terminated with a stop solution, and absorbance is quantified spectrophotometrically.

    Key Features and Performance Metrics

    • Sensitive Detection Capability: Exhibits an analytical sensitivity down to 123.87 ng/mL, facilitating the early tracking of low-level anti-drug antibody formations.

    • Extended Quantitative Range: Delivers a wide dynamic tracking range from 156.25 ng/mL to 10,000 ng/mL to accommodate diverse sample concentration tiers without immediate saturation.

    • Exceptional Intra-Assay Precision: Demonstrates excellent target reproducibility with a Coefficient of Variation (CV) of less than 10 percent, verified through sixteen separate replicate evaluations across three samples of known concentration on a single test plate.

    • High Inter-Assay Uniformity: Confirms outstanding day-to-day and batch-to-batch experimental reliability with a CV of less than 15 percent, validated across twenty-four distinct assay runs using three independent reference concentration samples.

    Technical Specifications

    • Catalog No.: KAD59501

    • Assay Configuration: Quantitative Bridging Sandwich Enzyme Immunoassay

    • Targeted Biomarker: Anti-Vosoritide (Anti-Drug Antibodies / ADA)

    • Validated Matrices: Serum and Plasma

    • Assay Range: 156.25 to 10,000 ng/mL

    • Analytical Sensitivity: 123.87 ng/mL

    • Solid-Phase Target: Recombinant Vosoritide

    • Detection Enzyme Layer: Biotin-Vosoritide / Streptavidin-HRP Conjugate

    Applications and Workflow Summary

    This bridging sandwich ELISA platform is highly optimized for therapeutic drug immunogenicity monitoring and downstream pharmacokinetic profiling. Investigators should observe the following guidelines:

    • Dilution and Layout: Unknown serum or plasma matrices must be screened alongside the provided reference standards. Samples exhibiting target concentrations exceeding the maximum range of 10,000 ng/mL must be diluted empirically in standard assay matrix buffer prior to running the assay.

    • Analysis Requirements: To achieve absolute quantification accuracy, investigators must generate a standard curve simultaneously during every plate run, plotting standard absorbance profiles against log-transformed concentration values.

    Handling, Stability and Storage

    • Kit Shipping: Distributed under secure, temperature-controlled conditions on blue ice or chilled gel packs to safeguard protein matrix and enzyme binding configurations.

    • Operational Shelf Life: When the kit is stored continuously at the recommended temperature for 6 months, the internal signal intensity and enzymatic reactivity profile degrade by less than 20 percent.

    • Storage Guidance: Keep the complete kit stored strictly at the manufacturer-specified refrigeration temperature upon receipt. Ensure that unused microplate wells remain sealed within their original desiccant pouch to guard against moisture compromise.

Heading 6

Related Products

bottom of page